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Fusobacterium nucleatum (Fn) has been associated
with colorectal cancer (CRC), but causality and
underlying mechanisms remain to be established.
We demonstrate that Fn adheres to, invades, and
induces oncogenic and inflammatory responses to
stimulate growth of CRC cells through its unique
FadA adhesin. FadA binds to E-cadherin, activates
b-catenin signaling, and differentially regulates the
inflammatory and oncogenic responses. The FadA-
binding site on E-cadherin is mapped to an
11-amino-acid region. A synthetic peptide derived
from this region of E-cadherin abolishes FadA-
induced CRC cell growth and oncogenic and inflam-
matory responses. The fadA gene levels in the colon
tissue from patients with adenomas and adenocarci-
nomas are >10–100 times higher compared to normal
individuals. The increased FadA expression in CRC
correlates with increased expression of oncogenic
and inflammatory genes. This study unveils a me-
chanism by which Fn can drive CRC and identifies
FadA as a potential diagnostic and therapeutic target
for CRC.
INTRODUCTION
The human intestinal microbiome contains >1,000 different
species, totaling 1014 microorganisms, and plays an extremely
important role in the maintenance of the normal physiology of
the gut, including energetic metabolism, proliferation and
survival of epithelial cells, and protection against pathogens
(Tremaroli and Ba¨ckhed, 2012). The microbiota exerts both
beneficial and detrimental effects on host contributing to health
or disease (Sekirov et al., 2010). Recently, two research teams
simultaneously reported overabundance of a specific microor-
ganism, Fusobacterium nucleatum (Fn), in colorectal carcinomaCell Hostissues (Castellarin et al., 2012; Kostic et al., 2012). However, it
was unknown if Fn was a cause or a consequence of CRC.
Fn is an opportunistic commensal anaerobe in the oral cavity,
implicated in various forms of periodontal diseases. Outside the
oral cavity, it is one of the most prevalent species in extraoral
infections (Han, 2011). It is highly prevalent in intrauterine infec-
tion associated with pregnancy complications such as preterm
birth, stillbirth, and neonatal sepsis (Han et al., 2009; 2010;
Wang et al., 2013). Fn adheres to and invades endothelial and
epithelial cells, a mechanism likely utilized for its systemic
dissemination (Han et al., 2000; 2004). The attachment and inva-
sion take place via adhesin FadA, a virulence factor identified
from Fn (Han et al., 2005; Xu et al., 2007). Immunofluorescent
staining of nonpermeabilized Fn using anti-FadA monoclonal
antibodies showed that FadA is expressed on the bacterial sur-
face (Ikegami et al., 2009).
FadA is highly conserved among Fn (Han et al., 2005). It exists
in two forms: the nonsecreted intact pre-FadA consisting of 129
amino acid (aa) residues and the secreted mature FadA (mFadA)
consisting of 111 aa without the 18 aa signal sequence (Han
et al., 2005). The mFadA monomer is predominantly a-helical
and forms a hairpin-like structure (Nithianantham et al., 2009).
The monomers are linked together in a head-to-tail pattern to
form uniformly long and thin filaments, with no binding activity
(Te´moin et al., 2012). When mFadA is mixed with pre-FadA,
they form active complex FadAc, consisting of heterogeneous
filaments, presumably due to varying degrees of filament
bundling (Xu et al., 2007; Te´moin et al., 2012). We have recently
demonstrated that the vascular endothelial (VE) cadherin
(CDH5), a member of the cadherin superfamily, is a receptor
for FadA that is required for Fn to attach and invade endothelial
cells (Fardini et al., 2011). The receptor for FadA on epithelial
cells was not identified.
In the present study, we demonstrate that FadA binds to
E-cadherin on CRC and non-CRC cells, mediating Fn attach-
ment of and invasion into the epithelial cells. FadA modulates
E-cadherin and activates b-catenin signaling, leading to in-
creased expression of transcription factors, oncogenes, Wnt
genes, and inflammatory genes, as well as growth stimulation
of CRC cells. Further, we show that while FadA binding to CRCt & Microbe 14, 195–206, August 14, 2013 ª2013 Elsevier Inc. 195
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ization mediated by clathrin is needed to activate the inflam-
matory genes. This study reveals a mechanism by which Fn
contributes to CRC and identifies FadA as a potential diagnostic
and therapeutic target for CRC.
RESULTS
Fn Stimulates Human CRC Cell Proliferation
Wild-type Fn 12230 significantly stimulated proliferation of
human colon cancer cells HCT116, DLD1, SW480, and HT29,
but only weakly stimulated RKO. It did not stimulate the noncan-
cerous human embryonic kidney (HEK) 293 cells. Compared to
the untreated cells or those incubated with E. coli DH5a, the
growth stimulation increased by approximately 100% for
HCT116, DLD1, SW480, and HT29, but only 18% for RKO, after
72 hr (Figure 1A). The fadA-deletion mutant US1 weakly stimu-
lated the growth of all cancer cell lines. The fadA-complementing
clone USF81 restored proliferation of HCT116, DLD1, SW480,
and HT29 to the wild-type level. Furthermore, HCT116 growth
was enhanced by purified FadAc in a dose-dependent manner,
with the maximum stimulation observed at 1 mg/ml, while
mFadA exhibited no stimulatory effect (Figure 1B). Neither
FadAc nor mFadA stimulated growth of RKO. These results indi-
cate that stimulation of CRC cells by Fn is FadA dependent.
FadA Binds to E-Cadherin on CRC Cells
To investigate the mechanism by which FadA stimulates CRC
cell growth, we set out to identify CRC cell receptors for FadA.
It was previously shown that FadA binds to VE-cadherin on
endothelial cells (Fardini et al., 2011). Cadherins are a large fam-
ily of calcium-dependent cell adhesion glycoproteins, each
composed of five extracellular repeat domains (EC1–EC5),
a transmembrane domain, and a highly conserved cytoplasmic
tail that binds other cytoplasmic components including
b-catenin (Gumbiner, 2005) (Figure 2A). Given the 33.5% similar-
ity between VE- and endothelial (E)-cadherins, we speculated as
to whether FadA also bound to E-cadherin. E-cadherin is present
at different levels on epithelial cells, including the noncancerous
HEK 293 and the CRC cells, except RKO (Figure 2B). FadA
binding to E-cadherin was directly tested by coimmunoprecipi-
tation. FadAc coprecipitated with E-cadherin, while mFadA did
not (Figure 2C). Using the glutathione S-transferase (GST) pull-
down assay, we determined that FadAc bound specifically to
EC5 of E-cadherin, but not to EC1–EC4, the transmembrane,
or the cytoplasmic domains (Figure 2D). Deletions of various
regions in EC5 showed that region 3 was responsible for FadA
binding (Figure S2 available online; see also below).
FadA Promotes Fn Attachment and Invasion of
E-Cadherin-Expressing Cells
Attachment and invasion are hallmarks of Fn. Thus, we tested
the role of FadA binding to E-cadherin in these processes. Fn
attachment and invasion of noncancerous HEK 293 cells was
inhibited by mouse monoclonal antibody HECD-1 raised against
the extracellular domain of E-cadherin (Figure S3A). Deletion of
fadA (US1) severely impaired the ability of Fn to bind and invade
HEK 293, whereas the fadA-complemented clone USF81
restored the activities. Downregulation of E-cadherin expression196 Cell Host & Microbe 14, 195–206, August 14, 2013 ª2013 Elseviby small interfering RNA (siRNA) in HEK 293 significantly
inhibited attachment and invasion by wild-type Fn and USF81
(Figure S3B). These results indicate that Fn attachment and inva-
sion of HEK 293 requires FadA and E-cadherin.
Similar observations were made with CRC HCT116 cells
expressing E-cadherin. US1 (fadA) was defective in the attach-
ment and invasion of HCT116, compared to wild-type Fn or
USF81 (fadA+) (Figure 3A). Inhibition of E-cadherin expression
by siRNA reduced attachment and invasion (Figure 3A). In
contrast, no difference was observed among Fn 12230, US1,
and USF81 in their weak binding and invasion of the non-E-cad-
herin-expressing RKOcells (Figure 3B). Transfection of RKOwith
the full-length E-cadherin led to increased binding and invasion
by Fn 12230 and USF81 to levels comparable to those observed
in HCT116 (Figure 3B). These results indicate that FadA medi-
ates Fn attachment and invasion of CRC cells via E-cadherin.
E-cadherin can be internalized via clathrin (Bryant and Stow,
2004). Pitstop2, a clathrin inhibitor (von Kleist et al., 2011), pre-
vented Fn invasion of HCT116 without affecting attachment (Fig-
ure 3C). Fn stimulated expression of the inflammatory genes,
including NF-kB and cytokines interleukin-6 (IL-6), IL-8, and IL-
18 from HCT116 (Figure 3D). Such stimulation was abolished
in the presence of the clathrin inhibitor, indicating that invasion
was required for the stimulation of inflammation (Figure 3D).
Identification of Inhibitory Peptides to Prevent Fn
Attachment and Invasion
Since FadA bound to the EC5 domain of E-cadherin, we tested
the role of EC5 in Fn attachment and invasion. Fn attachment
and invasion of HCT116 was inhibited by purified GST-EC5
fusion protein in a dose-dependent manner, with maximum
inhibition observed at 0.1 mM (Figures 4A and 4B). Synthetic
peptides derived from different regions of EC5 were then
tested for their ability to inhibit Fn attachment and invasion
(Figures 4A and 4C). Peptide 3, corresponding to region 3, ex-
hibited inhibitory effects similar to those of EC5 (Figure 4C). To
determine the minimal sequences required for inhibition,
sequential deletions of peptide 3 were generated. The results
showed that the 11 aa peptide (ASANWTIQYND) was the mini-
mum required and was designated as the inhibitory peptide
(IP) (Figure 4D).
FadA Promotes CRC Cell Proliferation via E-Cadherin
Stimulation of HCT116 growth by Fnwas inhibited by the CDH1-
specific siRNA, EC5, and the inhibitory peptide (Figure 1C). In the
non-E-cadherin-expressing RKO cells, transfection of the full-
length E-cadherin resulted in growth stimulation by Fn (Fig-
ure 1D). As in HCT116, such stimulation was diminished by
EC5 and the inhibitory peptide (Figure 1D). Similar observations
were made using purified FadAc instead of Fn (Figure S1). These
results elucidate the critical role of E-cadherin in promoting Fn-
driven CRC cell growth.
FadAc Activates E-Cadherin-Mediated Cellular
Signaling
To investigate the downstream events subsequent to FadA bind-
ing to E-cadherin, HCT116 cells were fractionated following in-
cubation with purified FadA. FadAc, but not mFadA, bound to
the HCT116 membranes within 5 min of incubation, leading toer Inc.
Figure 1. Fn and FadA Stimulate Proliferation of Human Colon Cancer Cells via E-Cadherin
(A) Wild-type Fn (Fn) and the fadA-complementing USF81 (fadA+) stimulated proliferation of human CRC cells HCT116, DLD1, SW480, and HT29, compared to
untreated cells or those incubated with E. coli. US1 (fadA) only weakly stimulated their growth. Fn, USF81, and US1 all weakly stimulated the growth of CRCRKO
cells, but not the noncancerous HEK 293 cells.
(B) Purified FadAc stimulated HCT116 cell growth in a dose-dependent manner, while mFadA did not. Neither FadAc nor mFadA stimulated RKO cell growth.
(C) Suppression of Fn-stimulated cell growth by inhibiting E-cadherin. Fn-stimulated HCT116 growth was inhibited by siRNA specific for CDH1, GST-EC5 fusion
protein, and the inhibitory peptide (IP), but not by nonspecific siRNA, GST, or the control peptide (CP).
(D) Fn stimulated the growth of RKO cells transfected with CDH1, but not mock-transfected RKO. Growth stimulation of CDH1-transfected RKO cells was sup-
pressed by GST-EC5 and the inhibitory peptide, but not by GST or the control peptide. The results are presented as mean ± SD. ***p < 0.001. See also Figure S1.
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Figure 2. E-Cadherin Is a FadA Receptor
(A) Schematic representation of the E-cadherin
(CDH1) structure. E-cadherin has five extracellular
cadherin (EC) repeats, numbered EC1–EC5 start-
ing from the N terminus. TM, transmembrane
domain; C, cytoplasmic domain.
(B) E-cadherin is expressed in epithelial HEK 293
cells and most CRC cells. E-cadherin in HEK 293
and human CRC cell lines HCT116, RKO, HT29,
SW480, and DLD1 was examined by western blot.
Human umbilical vein endothelial cells (HUVECs)
were included as a negative control. The endog-
enous GAPDH was used as a loading control.
(C) E-cadherin coimmunoprecipitates with FadAc.
HEK 293 cell lysate expressing E-cadherin was
mixed with E. coli lysates expressing FadAc or mFadA, or BSA, followed by incubation with mouse anti-CDH1 monoclonal antibodies (mAb), and captured with
protein A/G agarose beads. E-cadherin and FadA in the bead elutes were detected by western blot.
(D) FadA binds to EC5. Purified GST or GST fusion proteins carrying EC1–EC3, EC4, or EC5 were incubated with E. coli lysates expressing FadAc, followed by
capture with GST resin. The eluted components were subjected to SDS-PAGE, followed by Coomassie blue staining (top panel) and western blot (WB) using anti-
FadA mAb 5G11-3G8 (bottom panel). See also Figure S2.
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Mechanism of Fn in Colorectal CarcinogenesisE-cadherin phosphorylation on the membrane and internaliza-
tion (Figure 5A). This was accompanied by decreased phosphor-
ylation of b-catenin, b-catenin accumulation in the cytoplasma,
and translocation into the nucleus, resulting in activation of
b-catenin-regulated transcription (CRT), as evidenced by
increased expression of transcription factors lymphoid enhancer
factor (LEF)/T cell factor (TCF), NF-kB, and oncogenes Myc and
cyclin D1 (Figure 5A). It was previously shown that protein
tyrosine kinase (PTK) plays a crucial role in E-cadherin endocy-
tosis and recycling (Le et al., 2002). Interestingly, the PTK
inhibitor genistein not only prevented E-cadherin phosphoryla-
tion and internalization, but also abolished FadA binding to the
membranes and its internalization as well as the above-
described CRT activation (Figure 5A). These results suggest
that phosphorylation of E-cadherin or other cellular components
are required for activation of CRT. FadA may bind to phosphor-
ylated E-cadherin, or it may bind to nonphosphorylated
E-cadherin, which is then phosphorylated, leading to positive
feedback. The central role of b-catenin in regulating the cellular
responses was confirmed using HCT116 b-catenin/ cells,
which did not affect FadA binding to E-cadherin, phosphoryla-
tion of E-cadherin, or its internalization, but prevented all gene
activations tested in the nuclei (Figure 5A).
Although it did not affect FadA binding to E-cadherin or E-
cadherin phosphorylation on the membranes, the clathrin inhib-
itor inhibited FadA and E-cadherin internalization. A surprise
consequence was the divergent responses observed in the
nuclei. Translocation of b-catenin and expression of LEF/TCF,
Wnt, and oncogenes were unaffected. In contrast, no NF-kB
activation was observed (Figure 5A). These results indicate that
tumor growth and inflammatory responses, although both
requiring b-catenin, are differentially regulated.
The western blot analysis of protein levels was corroborated
with real-time quantitative PCR (qPCR) analysis of the
messenger RNA (mRNA) levels (Figures 5B–5E). While the PTK
inhibitor and CDH1-specific siRNA inhibited activation of tumor
growth and inflammatory genes, the clathrin inhibitor only in-
hibited the inflammatory genes, but not the Wnt or oncogenes.
To further confirm the role of FadA in CRT activation, we per-
formed confocal microscopy analysis and observed nuclei trans-198 Cell Host & Microbe 14, 195–206, August 14, 2013 ª2013 Elsevilocation of b-catenin in HCT116 in response to wild-type Fn, but
not to US1 (fadA) (Figure 5F). In addition, wild-type Fn and
USF81 (fadA+), but not US1 (fadA), activated the luciferase
reporter gene in TOPFlash carrying the b-catenin response
promoter, but not in FOPFlash carrying the b-catenin nonre-
sponse promoter (Figure 5G).
FadA Promotes E-Cadherin-Mediated CRC Tumor
Growth and Induction of Proinflammatory Cytokines in
Xenograft Mice
To examine the effects of FadA and Fn on CRC cell growth
in vivo, HCT116 cells were inoculated into nude mice, followed
by treatment with either purified protein or bacteria. Tumor
growth was increased by 20% after 3 weeks of treatment by
FadAc, compared to those treated with mFadA or BSA (Figures
6A and 6D). No increase was detected in the presence of
0.01 mmol inhibitory peptide, indicating the role of FadA binding
to E-cadherin in tumor growth (Figures 6B and 6D). FadAc had no
stimulatory effect on the non-E-cadherin-expressing RKO
(Figure 6C).
When wild-type Fn was injected into HCT116 xenografts,
abscess formation was observed within 3–5 days (data not
shown). Immunohistochemical analysis using anti-Fn antibodies
showed that wild-type Fn invaded the tumor tissues, while
neither US1 (fadA) (Figure 6E) nor E. coli DH5a did (data not
shown). Fn invasion was prevented by the inhibitory peptide,
but not by the control peptide (Figure 6E). FadAc (Figure S4)
and wild-type Fn (Figure 6F) stimulated the tumor growth genes
and the inflammatory genes to same extent, whichwere inhibited
by the inhibitory peptide, but not the control peptide, consistent
with the observations in vitro.
Patients with CRC and Precancerous Adenomas Have
Elevated fadAGene and Expression Levels Compared to
Normal Individuals
We examined fadA gene and expression levels in human colon
specimens from the following five groups: (1) normal, non-
cancerous individuals (n = 14); (2) normal tissues from patients
with precancerous adenomas (n = 16); (3) precancerous
adenomas (n = 16); (4) normal tissues from patients wither Inc.
Figure 3. Fn Adheres to and Invades E-Cadherin-Expressing CRC Cells
(A) Fn adheres to and invades the E-cadherin-expressing HCT116 via FadA and E-cadherin. The fadA-deletion mutant US1 (fadA) was defective for attachment
and invasion, compared to wild-type Fn and the fadA-complementing clone USF81 (fadA+). Transfection with siRNA to inhibit E-cadherin expression (siCDH1)
reduced attachment and invasion, while the nonspecific siRNA (siNS) did not.
(B) Wild-type Fn, US1, and USF81 were defective for attachment and invasion of the non-E-cadherin-expressing RKO cells. Transfection of full-length CDH1 into
RKO enhanced attachment and invasion by wild-type Fn and USF81 (fadA+), but not by US1 (fadA).
(C) The clathrin inhibitor, Pitstop2, inhibits Fn and USF81 (fadA+) invasion of HCT116 without affecting their attachment.
(D) Wild-type Fn stimulates expression of NF-kB and proinflammatory cytokines IL-6, IL-8, and IL-18 in HCT116, which was inhibited by the clathrin inhibitor.
Expression levels in untreated HCT116 were designated as 1. For (A), (B), and (D), the attachment and invasion levels were expressed as percent of bacteria
recovered from the host cells relative to the initial inoculum. For wild-type Fn, these levels reflect recovering approximately 9,000 cfu per well (in a 96-well plate)
from the attachment assay and approximately 2,000 cfu per well from the invasion assay. The invasion level of E. coliDH5a into HCT116 was <0.01%, i.e., <20 cfu
recovered per well (data not shown). For (C), the original attachment (4.4%±0.8%) and invasion (1.3%± 0.1%) levels without inhibition were designated as 100%,
and the relative inhibition values were shown. The results are presented as the mean ± SD. ***p < 0.001. See also Figure S3.
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A stepwise increase of fadA gene copies was observed from
group 1 to groups 2–4 and from groups 2–4 to group 5,
with >1 log difference between each step (Figure 7A). The
biggest difference was observed between the noncancerous
controls and CRC, with a >2 log difference (Figure 7A). Similar
observations were made when Fn-specific 16S ribosomal RNA
(rRNA) gene copies were measured (data not shown). The
FadA mRNA levels in the colon tissues, when normalized to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), also
showed a stepwise increase correlating with the fadA gene
copy numbers (data not shown). When the fadA mRNA levels
were normalized to Fn 16S RNA to reflect fadA expression in
Fn, a significant increase was only observed in the carcinoma
tissues (Group 5), indicating that Fn exhibits increased virulence
in CRC compared to the normal and precancerous tissues
(Figure 7B). Consistent with the increase of fadA, expression
of a representative Wnt gene, Wnt7b, and a representative
inflammatory gene, NFkB2, was also significantly increased in
CRC, corroboratingwith the results obtained in vitro and in xeno-
graft mice (Figures 7C and 7D).
DISCUSSION
CRC is the second leading cause of cancer death in men and
women combined in the US. (ACS, 2012). Worldwide, over oneCell Hosmillion new cases are diagnosed each year (Bartlett and Chu,
2012). Understanding the mechanisms of CRC and identifying
risk factors are important to human health. Increasing evidence
supports a relationship between infective agents and various
human malignancies (Plottel and Blaser, 2011). Previous studies
have provided mechanistic insights into the microbial involve-
ment in the development of CRC (Arthur et al., 2012; Cuevas-
Ramos et al., 2010; Lee et al., 2010; Wu et al., 2009). It was
reported that Bacteroides fragilis enterotoxin BFT cleaves E-
cadherin to activate b-catenin signaling (Wu et al., 1998; 2003).
Here, we report a mechanism by which Fn modulates E-cad-
herin/b-catenin signaling.
Fn significantly stimulates proliferation of E-cadherin-express-
ing CRC cells, but not those without E-cadherin. The stimulation
requires FadA, an E-cadherin ligand. The fadA-deletion mutant
US1 has weak stimulatory activity. These observations indicate
that the interactions between FadA and E-cadherin play a
primary role in promoting CRC tumor growth, while the FadA-
independent pathway(s) play a minor role.
E-cadherin is a tumor suppressor that functions through
b-catenin (Bryant and Stow, 2004; Peifer and Polakis, 2000). It
has been previously reported that E-cadherin is present in
100% of the normal mucosa of CRC patients and 75% of cancer
specimens (Mohri, 1997). Loss or heterogeneous expression of
E-cadherin correlated with advanced stages of CRC and poor
prognosis (Mohri, 1997; Dorudi et al., 1993). FadA binding tot & Microbe 14, 195–206, August 14, 2013 ª2013 Elsevier Inc. 199
Figure 4. Identification of Synthetic Peptides to Inhibit Fn Attachment and Invasion of HCT116 Cells
(A) Partial amino acid sequence of the EC5 domain. The regions and the corresponding peptides (pep) are shown above the sequence. The sequences cor-
responding to the inhibitory peptide (IP, see below) are underlined. Peptide 4 was the control peptide (CP) in all studies.
(B) Purified GST-EC5 fusion protein inhibits wild-type Fn attachment and invasion of HCT116 in a dose-dependent manner.
(C) Fn attachment and invasion of HCT116 cells were inhibited by a synthetic peptide corresponding to region 3 (pep 3) on the EC5 domain, not by peptides
corresponding to regions1 and 2 or 4.
(D) The inhibitory effects of synthetic oligopeptides carrying sequential deletions from the N and C termini of region 3 on Fn attachment and invasion. Deletion of 3
residues from the N terminus and 1 residue from the C terminus did not affect the inhibitory function. An 11 aa peptide (ASANWTIQYND) was found as the
minimum sequence required for inhibition of Fn attachment and invasion. All values were expressed relative to those without inhibition, which were designated as
100%. The actual attachment and invasion levels were 6.3% ± 1.4% and 1.6% ± 0.1%, respectively, for (B); 5.9% ± 0.7% and 1.4% ± 0.1%, respectively, for (C);
and 5.3 ± 0.5% and 1.3 ± 0.1%, respectively, for (D). The results are presented as mean ± SD. ***p < 0.001.
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Figure 5. FadAc Activates E-Cadherin-Mediated Cellular Signaling
(A) Western blotting was used to detect the following: (1) FadAc, but not mFadA, binds to the membranes of HCT116, accompanied by phosphorylation of E-
cadherin on the membrane; (2) E-cadherin and FadA are internalized, phosphorylation of b-catenin is reduced, and total b-catenin accumulates in the cyto-
plasma; and b-catenin translocates and transcription factors lymphoid enhancer factor (LEF)/T cell factor (TCF), NF-kB, and oncogenes Myc and cyclin D1 are
activated in the nuclei. Protein tyrosine kinase (PTK) inhibitor genistein inhibits all FadAc-activated functions. No gene activation was detected in the HCT116
b-catenin/ cells, despite binding and internalization of FadA and E-cadherin. The clathrin inhibitor Pitstop2 prevented E-cadherin and FadA internalization and
activation of NF-kB, but did not affect nuclei translocation of b-catenin or expression of LEF/TCF, Myc or cyclin D1. The epidermal growth factor receptor (EGFR),
GAPDH, and proliferating cell nuclear antigen (PCNA) were used as loading controls for membrane, cytoplasmic, and nucleus, respectively, and for examination
for cross-contamination between the subcellular fractions.
(B–E) FadAc, but not mFadA or BSA, activates expression of Wnt signaling genes 7a, 7b, and 9a (B); oncogenes Myc and cyclin D1 (C); clathrin (cltb) and protein
tyrosine kinase genes (ptk6) (D); and NF-kB and proinflammatory cytokines IL-6, IL-8, and IL-18 (E) in wild-type, but not in b-catenin knockout HCT116 cells
following 2 hr incubation as determined by qPCR. The clathrin inhibitor inhibited expression of the inflammatory genes, but not theWnt or oncogenes. Expression
levels in untreated HCT116 cells were designated as 1.
(F) Wild-type Fn (Fn), but not US1 (fadA), induces nuclei translocation of b-catenin following 2 hr incubation, as observed by confocal microscopy. b-catenin was
stained with Alexa 634 (red) and the nuclei with DAPI (blue). The purple color in the merged images indicates translocation of b-catenin into the nuclei.
(G) Luciferase reporter gene expression following HCT116 transfection with TOPFlash (activated by b-catenin) or FOPFlash (insensitive to b-catenin activation).
Fnwas incubated with the transfected cells at an moi of 1,000:1 for 2 hr, followed bymeasurement of the luciferase activity. Values obtained with FOPFlash were
designated as 1, and those obtained with TOPFlash were expressed as fold changes. Data are presented as mean fold changes ± SD of two independent
experiments, each performed in triplicate. ***p < 0.001.
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Mechanism of Fn in Colorectal CarcinogenesisE-cadherin inhibits its tumor suppressor activity, resulting in
increased CRT. This phenotype is consistent with the adeno-
matous polyposis coli (APC) mutation, the most common
mutation in CRC (Kinzler and Vogelstein, 2002). The four human
colon cancer cell lines stimulated by FadA, HCT116, DLD1,
SW480, and HT29, carry either an APC mutation (DLD1,
SW480, and HT29) (Yang et al., 2006) or a b-catenin mutation
(HCT116) (Morin et al., 1997), and thus have increased CRT
background (Chan et al., 2002). FadA, both in purified form
and in Fn, further enhanced CRT and stimulated the growth of
these cells, attesting to its carcinogenic potency. Interestingly,Cell HosFadA does not stimulate the growth of the noncancerous HEK
293, suggesting that it promotes carcinogenesis after a mutation
occurs.
FadA is the major component mediating Fn attachment and
invasion (Xu et al., 2007). It binds to an 11 aa region in the EC5
domain on E-cadherin and is internalized with E-cadherin. The
11 aa inhibitory peptide inhibits Fn from binding and invading
and abolishes all subsequent host responses, including tumor
growth and inflammatory responses. Thus, this inhibitory pep-
tide not only prevents Fn colonization but also inhibits Fn-medi-
ated oncogenesis.t & Microbe 14, 195–206, August 14, 2013 ª2013 Elsevier Inc. 201
Figure 6. FadA Promotes E-Cadherin-Mediated CRC Tumor Growth and Induction of Proinflammatory Cytokines in Xenograft Mice
HCT116 or RKO cells were injected subcutaneously and bilaterally into female nude mice, which were then randomized (five per group) to receive treatments.
(A–C) FadAc stimulates HCT116, but not RKO, xenograft growth. Purified FadAc, mFadA, or BSAwere injected into xenografts of HCT116 either alone (A) or along
with the inhibitory (IP) or control (CP) peptides (B) or RKO alone (C) in nude mice. IP alone is injected into HCT116 as a negative control (B).
(D) Representative tumors from (A) and (B) are shown. The first day of protein injection was designated as day 1. All tumors look the same on day 1. Notice the size
increase of the tumor treated with FadAc and FadAc + CP on day 21 compared to other tumors on the same day.
(E) Immunohistochemical staining of xenografts infected with wild-type Fn (Fn), alone and with the inhibitory or control peptides, and the fadA-deletion mutant
US1 (fadA) using rabbit anti-Fn polyclonal antibodies. For controls, xenografts infected with wild-type Fn were stained with pre-serum, and xenografts infected
with E. coli DH5a were stained with anti-Fn antibodies (data not shown).
(F) Wild-type Fn induces expression of NF-kB and proinflammatory cytokines IL-6, IL-8, and IL-18; Wnt 7a, 7b, and 9a; and Myc and cyclin D1 in HCT116 xe-
nografts, as determined by qPCR. The inductions were inhibited by IP, but not by CP. E. coli only weakly induced IL-6. The results are presented as mean ± SD.
***p < 0.001. See also Figure S4.
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Mechanism of Fn in Colorectal CarcinogenesisInflammation plays a key role in CRC oncogenesis (Baron and
Sandler, 2000; Ekbom et al., 1990). In this issue, Kostic et al.
(2013) showed that Fn generates a proinflammatory microenvi-
ronment that is conducive for colorectal neoplasia progression
(Kostic et al., 2013). Both the observations herein and by Kostic
et al. (2013) support that inflammatory stimulation by Fn further202 Cell Host & Microbe 14, 195–206, August 14, 2013 ª2013 Elsevireinforces the oncogenic potential of this microorganism. As
shown in the xenografts, FadA alone was able to stimulate the
inflammatory responses to the same extent as Fn, indicating
that FadA is the major stimulant of inflammation.
Our results reveal that tumor growth and inflammation are
differentially regulated, although both require b-catenin, theer Inc.
Figure 7. Quantification of fadA Gene Copies and FadA, Wnt7b, and NFkB2 Expression in Healthy Cells, Precancerous Adenomas, and Car-
cinomas
(A–D) DNA and RNA were extracted from full-thickness colon specimens from the following 5 groups: (1) normal, noncancerous controls (N; n = 14); (2) normal
tissues from patients with precancerous adenomas (N[ade]; n = 16); (3) precancerous adenomas (ade; n = 16); (4) normal tissues from patients with carcinomas (N
[crc]; n = 19); and (5) carcinomas (crc; n = 19). Gene copy numbers of fadA (A) were measured using DNA and determined using the standard curves. FadAmRNA
levels in Fnwere normalized to Fn 16 rRNA (B), andWnt7b (C) andNFkB2 (D)mRNA levels were each normalized to the endogenousGAPDH. The average value of
group 1 (N) was designated as 1, and the fold changes of the other groups were determined by comparing to group 1. The horizontal bars represent the median
values. For (B)–(D), the boxes show the 25th and 75th percentiles and the lines within the boxes the median values. Whiskers show the 10th and 90th percentiles.
*p < 0.05, **p < 0.01, and ***p < 0.001.
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Mechanism of Fn in Colorectal Carcinogenesismaster regulator. It is often difficult to distinguish the roles of
adherence and invasion, as these two processes are tightly
correlated (Martin et al., 2004; Swidsinski et al., 1998), with the
former being a prerequisite for the latter. Using the clathrin inhib-
itor, we are able to functionally separate Fn attachment from
invasion and demonstrate that although invasion is not required
for tumor growth, it is essential for the induction of inflammation,
which is consistent with a previous report that the invasive
potential of Fn correlates with the host inflammatory bowel dis-
ease (IBD) status (Strauss et al., 2011).
The mechanistic investigation is corroborated with studies in
humans. Previous studies have shown that Fn is readily detected
in the tissues, but not in the stools (Chen et al., 2012). This may
be due to its adherent and invasive properties. Hence, we exam-
ined the presence of Fn in colon tissue specimens, rather than
stools. The results unveil a stepwise increase of fadA gene
copies from the baseline of normal individuals to adenomas
and normal tissues adjacent to adenomas and adenocarci-Cell Hosnomas and to adenocarcinomas. The normal tissues from
patients with adenomas and adenocarcinomas are thus ‘‘pseu-
donormal’’ compared to the noncancerous controls. This is
consistent with the findings by McCoy et al. (2013). Given the
fact that FadA mediates Fn binding to both CRC and non-CRC
cells, and the fact that the normal tissues also express E-cad-
herin, it is not surprising that Fn can colonize both tumor and
nontumor sites. Elevated Fn colonization in the normal tissues
may predispose the host to the development of adenomas
and/or adenocarcinoma, with carcinogenesis being accelerated
when a mutation occurs. The fact that FadA expression levels in
Fn, as well as the host inflammatory and oncogenic responses,
are increased in the cancerous tissues, but not in the precancer-
ous tissues, further supports this notion.
The finding of elevated fadA levels in the precancerous state
implies translational potential. Compared to the metagenomic
approach in the previous studies (Castellarin et al., 2012; Kostic
et al., 2012), qPCR is significantly less time consuming and moret & Microbe 14, 195–206, August 14, 2013 ª2013 Elsevier Inc. 203
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Mechanism of Fn in Colorectal Carcinogenesiscost effective, which is suitable for clinical purposes. The fadA
gene is unique to Fn (Han et al., 2005) and, hence, is an ideal
potential diagnostic marker to identify individuals at risk for
developing adenomas and/or adenocarcinomas. Based on the
results shown in Figure 7, it is possible that diagnostic criteria
may be developed to define healthy, precancerous, and
cancerous states according to fadA gene copy levels. One limi-
tation of the current study is the small sample size. The potential
use of fadA as a diagnostic marker needs to be evaluated in a
much larger prospective cohort. Future studies are also war-
ranted to examine the use of the inhibitory peptide and/or its
derivatives to eradicate Fn, either as a preventive therapy for
individuals with increased risk or as a complementary therapy
for those with CRC.
In conclusion, we have elucidated an oncogenic mechanism
of CRC. Findings from this study will significantly impact our
understanding, diagnosis, prevention, and treatment of CRC.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Cell Cultures, Construction of Plasmids, Protein
Purification, and GST Pull-Down Assays
Bacteria and human cell lines were cultured as previously described (Fardini
et al., 2011; Han, 2006; Zhang et al., 2013). Extracellular (EC) domains of E-
cadherin were amplified by PCR from pcDNA3-E-cadherin (Addgene) vector
using primers listed in Table S1. Protein expression and purification as well
as GST pull-down assays were all performed as previously described (Fardini
et al., 2011; Xu et al., 2007).
Tissue Culture Attachment and Invasion Assays
These assays were performed as previously described (Han et al., 2000).
Briefly, cells were seeded in 24-well or 96-well plates at 8 3 104 cells or
2.53 104 cells per well in the growth medium and grown to 100% confluency.
Bacteria were added to the cells at a multiplicity of infection (moi) of 5.
Following 1 hr incubation at 37C in 5% CO2, the monolayers were washed
3 times with Dulbecco’s phosphate-buffered saline (DPBS) (pH 7.1) supple-
mented with Ca2+ and Mg2+. Cells were lysed with water for 20 min at 37C.
Serial dilutions of the lysates were plated onto blood agar plates to enumerate
the total cell-associated bacteria. For invasion assays, the bacteria were incu-
bated with the monolayers at 37C for 4 hr, followed by washes with PBS.
Fresh media containing 300 mg/ml gentamicin and 200 mg/ml metronidazole
were added to the monolayers and incubated for an additional hour to kill
extracellular bacteria. The cells were then washed and lysed with water as
described above. The levels of attachment and invasion were expressed as
the percentage of bacteria recovered following cell lysis relative to the total
number of bacteria initially added. Each experiment was performed in triplicate
and repeated at least twice.
Antibodies, Peptides, and Western Blot Analysis
The following antibodies were used: anti-FadA monoclonal antibody (mAb)
5G11-3G8 (Xu et al., 2007), mAb anti-CDH1 (Abcam or Cell Signaling Technol-
ogy), polyclonal anti-phospho-CDH1 (ECM Biosciences), mAb anti-GAPDH
(Invitrogen), mAb anti-b-catenin (R&D Systems), polyclonal anti-phospho-
b-catenin (Cell Signaling Technology), mAb anti-LEF/TCF1 (Invitrogen), mAb
anti-NF-kB (Invitrogen), mAb anti-Myc (Cell Signaling Technology), mAb
anti-cyclin D1 (Cell Signaling Technology), mAb anti-EGFR (Cell Signaling
Technology), mAb anti-GAPDH (Cell Signaling Technology), mAb anti-PCNA
(Cell Signaling Technology), polyclonal goat anti-mouse or goat anti-rabbit
secondary antibody conjugated with horseradish peroxidase (HRP) (Pierce
Biotechnology). Peptides were synthesized by NEO Group Inc. Western blot
analyses were performed as previously described (Fardini et al., 2011).
Coimmunoprecipitation Assay
A total of 500 mg of HEK 293 cell lysate prepared with Co-IP Lysis/Wash Buffer
(Pierce) was mixed with 100 mg of BSA or E. coli lysate expressing FadAc or204 Cell Host & Microbe 14, 195–206, August 14, 2013 ª2013 ElsevimFadA, followed by the addition of mouse monoclonal anti-CDH1 antibodies.
The protein complex was captured by protein A/G agarose beads (Santa Cruz)
as previously described (Chan et al., 2002), followed by elution and western
blot analysis. An equal volume of the eluted components was loaded onto
SDS-PAGE.
DNA and siRNA Transfection
CDH1 transfections were performed as previously described (Lebreton et al.,
2011). siRNA assays were performed using the FlexiTube siRNA anti-CDH1
reagent and AllStars FlexiTube Control siRNA from QIAGEN according to
the manufacturer’s instructions.
Cell Proliferation Assay
CRC cells were seeded in 24-well plates at 13 104 cells per well in the growth
medium. Cells were untreated or incubated with FadAc or peptides at the indi-
cated concentration or with bacteria at an moi of 1000:1. Cell numbers were
counted at 24 hr intervals using a hemocytometer. Each experiment was per-
formed in triplicate and repeated at least twice.
Preparation of Subcellular Fractions
Cells were incubated with 1 mg/ml of FadAc or mFadA followed by the extrac-
tion of subcellular fractions. When indicated, 50 mM of the corresponding PTK
inhibitor (genistein) and clathrin inhibitor (Pitstop2) were preincubated with
cells for 1 hr. Membrane, cytosolic, and nuclei fractions were prepared using
the Compartmental Protein Extraction Kit (Millipore) according to themanufac-
turer’s instructions.
Luciferase Reporter Assay
HCT116 cells were seeded in 96-well plates at 2.5 3 104 cells per well in the
growth medium and grown to 100% confluency. Cells were transfected with
0.2 mg of TOPFlash, a luciferase reporter vector carrying TCF promoter
upstream of the luciferase gene and able to be activated by b-catenin, or
FOPFlash (with mutations rendering insensitivity to b-catenin activation), using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
On the following day, cells were incubated with bacteria at an moi of 1000:1 for
2 hr. Reporter assays were performed using the luciferase reporter system
(Promega). The experiment was performed in triplicate and repeated twice.
Immunofluorescent and Immunohistochemical Staining
Immunofluorescent staining of cells was performed as previously described.
Mouse anti-b-catenin mAb and Alexa Fluor 634-conjugated goat anti-mouse
polyclonal antibodies were used (Fardini et al., 2011). Immunohistochemical
(IHC) analysis of xenograft tumors was performed as previously described,
using rabbit anti-Fn polyclonal antibodies (Han et al., 2004). Preimmune serum
from the same rabbit was used as control.
Xenografts
The animal protocol was approved by the Case Western Reserve University
Institutional Animal Care and Use Committee. An inoculum of 5 3 106 cells
were injected subcutaneously (s.c.) and bilaterally into 4- to 6-week-old female
nude mice (5 per group) as previously described (Zhang et al., 2013). The mice
were randomized to receive one of the following: FadAc or mFadA (each at
80 mg) with or without peptide (0.01 mmol), BSA (0.01 mmol, i.e., 660 mg), or bac-
teria at 1 3 107 colony-forming units (cfu) at each inoculation site. Xenograft
volumes were calculated as previously described (Zhang et al., 2013).
Clinical Specimens
This study was approved by the University Hospitals of Cleveland Institutional
Review Board. A total of 19 cases diagnosed with colonic adenocarcinoma
and 16 cases of adenomas were retrieved from files at the Department of
Pathology of the University Hospitals Case Medical Center. Hematoxylin and
eosin (H&E) slides were reviewed to confirm the presence of adenocarcinoma
(or adenoma). A representative block of colon adenocarcinoma (or adenoma)
and a block of normal colon from the same patient were used. In addition,
normal colon tissues were derived from 14 individuals undergoing resection
for benign colon pathology or resection of adjacent organs. Exclusion criteria
were history of gastrointestinal malignancies, presence of prominent inflam-
mation or abscess, and history of IBD. All cases were from within the laster Inc.
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Mechanism of Fn in Colorectal Carcinogenesis12 months. Genomic DNA was extracted from formalin-fixed paraffin-
embedded tissue samples as previously described (Tang et al., 2009). RNA
was extracted using PureLink FFPE Total RNA Isolation Kit (Invitrogen) or
RNeasy FFPE Kit (QIAGEN).
Real-Time Quantitative PCR
Total RNA was extracted from CRC cells, xenografts, or clinical specimens.
cDNA synthesis and real-time PCR were performed as previously described,
using primers listed in Table S1 (Lebreton et al., 2011). Data were analyzed
by the DDCt method (Livak and Schmittgen, 2001) and normalized to the
GAPDH or Fn-specific 16S rRNA. To quantify the fadA gene copies, plasmid
carrying fadA was serially diluted to 102–108 fadA copies/ml and used to
generate standard curves for Ct values. The fadA gene copies in the clinical
samples were calculated based on the standard curves. Each experiment
was performed in triplicate and repeated at least three times.
Statistical Analysis
The differences between groups were examined by two-tailed one-way
ANOVA followed by Student-Newman-Keuls (SNK) test. For the clinical spec-
imens, the Kruskal-Wallis nonparametric test was performed, followed by the
Conover test. p < 0.05 was considered statistically significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and one table and can be
found with this article online at http://dx.doi.org/10.1016/j.chom.2013.07.012.
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